High-Resolution Assessment of Extracranial Plaques

This is an interventional treatment trial for Cerebral Atherosclerosis focused on measuring atherosclerosis, plaque burden, Evolocumab, High-Resolution assessment, OCT Read More

Inclusion Criteria:

1. Age ≥ 18 years old, regardless of sex;
2. Cerebrovascular angiography examination was performed, and the imaging characteristics were consistent with: 1) The stenosis degree of internal carotid artery (starting from C1 segment) or vertebral artery (starting from vertebral artery to V1 segment) was 30%-69%; 2) The target vessel for imaging has not undergone or intends to undergo revascularization and must be available for OCT imaging catheter;
3. Fasting LDL-C level ≥ 1.8mmol/L;
4. Participants who understand and sign the informed consent form voluntarily.

Exclusion Criteria:

1. Intolerant to atorvastatin and Rosuvastatin;
2. A history of major surgery or endovascular therapy within 3 months before the screening period;
3. Stenosis or occlusion of arteries not caused by atherosclerosis, such as arterial dissection, Moya-moya disease, vasculitis, radio-vascular disease, or fibromuscular dysplasia;
4. Abnormal liver function (ALT > 3 times the upper limit of normal value);
5. Abnormal renal function (eGFR < 45 mL/min/1.73m2);
6. Thrombocytopenia (PLT < 100G/L);
7. The life expectancy of the subjects is less than 6 months;
8. During the screening period, there are known serious life-threatening diseases (e.g., hematological disease, malignancy), unstable vital signs or the need for continuous monitoring or a dying state;
9. Patients have been included in other studies that conflicts with this study;
10. Known allergy to any product or ingredient during administration;
11. Pregnant women, breastfeeding, or trying to become pregnant.
12. Other conditions considered inappropriate for enrollment by the investigators.